Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | CYP2U1 |
| Upstream (Parents) |
|---|
| (<<) ADRBK2 → CYP2U1 |
| (<<) AKAP12 → CYP2U1 |
| (<<) ANTXR2 → CYP2U1 |
| (<<) AXL → CYP2U1 |
| (<<) E2F1 → CYP2U1 |
| (<<) ELK3 → CYP2U1 |
| (<<) ITGB5 → CYP2U1 |
| (<<) NR3C1 → CYP2U1 |
| (<<) PAK4 → CYP2U1 |
| (<<) PTGER4 → CYP2U1 |
| (<<) RAP1A → CYP2U1 |
| (<<) RAVER1 → CYP2U1 |
| (<<) RECK → CYP2U1 |
| (<<) THOC4 → CYP2U1 |
| (<<) TK2 → CYP2U1 |
| (<<) UBE2C → CYP2U1 |
| (<<) VEGFC → CYP2U1 |
| Downstream (Children) |
|---|
| CYP2U1 → BCL2 (>>) |
| CYP2U1 → CCDC3 (>>) |
| CYP2U1 → CIRH1A (>>) |
| CYP2U1 → CXCL14 (>>) |
| CYP2U1 → EFEMP1 (>>) |
| CYP2U1 → GNB5 (>>) |
| CYP2U1 → GNG10 (>>) |
| CYP2U1 → HOPX (>>) |
| CYP2U1 → HSP90AA1 (>>) |
| CYP2U1 → IL1R1 (>>) |
| CYP2U1 → ITPR3 (>>) |
| CYP2U1 → KLF16 (>>) |
| CYP2U1 → LYNX1 (>>) |
| CYP2U1 → MTMR6 (>>) |
| CYP2U1 → OBSCN (>>) |
| CYP2U1 → PCDH7 (>>) |
| CYP2U1 → PELO (>>) |
| CYP2U1 → PFDN2 (>>) |
| CYP2U1 → PLK1 (>>) |
| CYP2U1 → PPAP2A (>>) |
| CYP2U1 → PRR5 (>>) |
| CYP2U1 → ROCK1 (>>) |
| CYP2U1 → SOX17 (>>) |
| CYP2U1 → STK17A (>>) |
| CYP2U1 → STX12 (>>) |
| CYP2U1 → TGFB2 (>>) |
| CYP2U1 → TUBA1A (>>) |
| CYP2U1 → UBE2I (>>) |
| CYP2U1 → ZNF575 (>>) |
